NovaBay Pharmaceuticals (NYSE:NBY) Earns Sell Rating from Analysts at started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBYGet Free Report) in a note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

NovaBay Pharmaceuticals Stock Performance

Shares of NBY opened at $0.35 on Monday. The company has a market cap of $1.46 million, a PE ratio of -0.03 and a beta of 2.84. NovaBay Pharmaceuticals has a 12-month low of $0.31 and a 12-month high of $4.08.

NovaBay Pharmaceuticals (NYSE:NBYGet Free Report) last released its earnings results on Thursday, August 10th. The company reported ($1.27) EPS for the quarter. NovaBay Pharmaceuticals had a negative net margin of 79.70% and a negative return on equity of 146.20%. The business had revenue of $4.61 million during the quarter. Analysts anticipate that NovaBay Pharmaceuticals will post -2.54 earnings per share for the current year.

About NovaBay Pharmaceuticals

(Get Free Report)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.

Featured Stories

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with's FREE daily email newsletter.